Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction

Leukemia & Lymphoma
H G DrexlerJ W Janssen

Abstract

In recent years many chromosomal translocations involved in leukemia and lymphoma have been defined at the molecular level. In addition to advancing the understanding of pathological mechanisms underlying the transformation process, the cloning and sequencing of the genes altered by the translocations have provided new tools for diagnosis and monitoring of patients. In particular, the polymerase chain reaction (PCR) methodology yields rapid, sensitive and accurate diagnostic and prognostic information. As leukemias carrying certain translocations confer a higher risk of treatment failure, it is important to identify accurately all positive cases in order to give appropriate therapy. An important new initiative in the diagnostical setting and anti-leukemic therapy is the early detection of minimal residual disease (MRD). If MRD, implying an increased risk of relapse, is reliably detected during apparent clinical remission, alternative strategies could be applied early while the malignant cell burden is still minimal. The PCR assays are clearly more sensitive than other methods of MRD detection including morphology, immunophenotyping and cytogenetics; treatment failure is first detectable by PCR followed by cytogenetic relapse an...Continue Reading

References

Jun 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayP G Pelicci
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·N R McCabeM O Diaz
May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K MorishitaJ N Ihle
Jan 1, 1992·Annual Review of Immunology·S J Korsmeyer
Nov 22, 1991·Science·R A Weinberg
Oct 1, 1991·The Journal of Experimental Medicine·B TyckoJ Sklar
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M A KennedyT H Rabbitts
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C L RosenbergA Arnold
Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H MiyoshiM Ohki
Dec 11, 1991·Proceedings of the National Academy of Sciences of the United States of America·S Ziemin-van der PoelJ D Rowley
Dec 25, 1991·Proceedings of the National Academy of Sciences of the United States of America·Y XiaR J Baer
Dec 1, 1991·British Journal of Haematology·S Izraeli, T Lion
Apr 11, 1991·Nature·T MotokuraA Arnold
Oct 1, 1991·Molecular and Cellular Biology·D A WithersT C Meeker
Mar 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayF Lo Coco
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C G PriceT A Lister
Nov 22, 1991·Science·E SolomonA D Goddard
Jan 25, 1991·Cell·J M Bishop
Jan 25, 1991·Cell·T Hunter
May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T BoehmT H Rabbitts
Jun 1, 1991·The Journal of Clinical Investigation·O G JonssonR G Smith
Sep 1, 1990·The Biochemical Journal·D S Latchman

❮ Previous
Next ❯

Citations

Jul 1, 1997·Leukemia Research·C BredouxH G Drexler
Jul 29, 1998·Leukemia Research·Y Matsuo, H G Drexler
Nov 27, 1999·Leukemia Research·C C UphoffH G Drexler
Sep 13, 2003·Cancer Letters·Orlev Levy-NissenbaumIsaac P Witz
Mar 10, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F WillekeR Ridder
Aug 26, 1998·Critical Reviews in Oncology/hematology·S Faderl, Z Estrov
Oct 18, 2003·Seminars in Cancer Biology·Christine Damm-WelkArndt Borkhardt
May 24, 2003·Trends in Molecular Medicine·Simone MocellinFrancesco M Marincola
Sep 30, 1998·British Journal of Haematology·K RitisP Sideras
Feb 17, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·C SambadeC Sundström
Jul 9, 2004·The Tohoku Journal of Experimental Medicine·Atsushi HoshinoTakeshi Sasaki
Apr 1, 1997·Leukemia & Lymphoma·J M HildenJ H Kersey
Nov 5, 1997·Annals of the New York Academy of Sciences·B KornhuberS Wehner

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.